AT-01 (ATX-011)

About Alethio Therapeutics

Alethio Therapeutics is a private, preclinical-stage biotech spin-out from the University of Oxford, founded in 2019 and based in Cambridge, UK. The company is focused on developing first-in-class, disease-modifying therapies for myeloproliferative neoplasms (MPNs), a group of incurable chronic blood cancers. Its pipeline is driven by the ARTEMIS platform, which integrates a vast repository of patient-derived data, advanced 'omics, and organoid models to identify and de-risk novel targets. Alethio emerged from stealth in late 2025 with two ADC programs and appointed a new CEO and Chair to advance its lead candidate towards clinical studies.

Therapeutic Areas